(MENAFN- Mid-East.Info) Dubai: Australian-based Eyetelligence, a developer of decision-making support software, and United Arab Emirates (UAE) based Alliance Care Technologies (ACT), a developer of innovative solutions in digital healthcare, have announced a strategic partnership at Precision Med Expo in Dubai to bring transformational AI Ophthalmology solutions to the UAE market.
The Preferred Partnership agreement signed at Precision Med Expo will provide stand-alone and hospital-based clinics with Glaucoma detection support, Referable Diabetic Retinopathy screening support with grading, and screening support for neovascular age-related macular degeneration (nAMD).
The signing ceremony was held in the Alliance Care Technologies booth at Precision Med Expo in Dubai, witnessed by Mounir Sankary, Australian Deputy Consul General for Dubai. Attendees representing Eyetelligence included Founder Prof. Mingguang He, MD PhD; CEO Rainer Grote, and Chief Strategy Officer Jason Sun. Alliance Care Technologies is represented by Founder and CEO Michele Tarnow, and Chief Medical Officer Dr. Aaron Han, MD, PhD.
The Eyetelligence team introduced this advanced technology to the UAE market at Precision Med Summit. The launch included an in-person presentation by Mingguang (Ming) He, MD, PhD, Professor of Ophthalmic Epidemiology,
Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences,
University of Melbourne; Head of Ophthalmic Epidemiology, Centre for Eye Research Australia. Prof. Ming is a global expert in the clinical adoption of artificial intelligence in medicine and is the founder of two Australian-based international MedTech companies, Eyetelligence and Eyerising, which bring to market Dr. Ming's AI technology and light therapy technology.
According to Prof. Ming:“AI has evolved from computer software in the laboratory to clinical adaptation in many image-driven practices, including ophthalmology. Enabled by a combination of the availability of large datasets and substantially improved computing power, deep learning algorithms (DLAs) have created unprecedented opportunities for substantially improved accuracy in automated detection and diagnosis of eye diseases. This development will make eye care less dependent on human input and therefore would improve accessibility, efficiency, and cost-effectiveness, making ocular disease diagnosis and management quicker, cheaper, and more consistent”.
Eyetelligence Assure is an advanced AI software solution that analyzes retinal images for features of the three major blinding eye diseases: glaucoma, referable diabetic retinopathy and referrable neovascular age-related macular degeneration. Backed by peer-reviewed publications and journals, Eyetelligence's deep learning technology is designed to empower clinicians to make more informed clinical decisions with speed, accuracy, and confidence to ensure the best health outcomes for their patients. Also available is Eyetelligence Microvascular, a non-invasive platform to detect early signs of cardiovascular disease based on a microvascular profile. Eyerising brings to market Eyerising Myproclear, which controls the progression of childhood Myopia with the world's first non-invasive, at-home device for Myopia control.
“We anticipate strong demand for this technology across the region” says Michele Tarnow, CEO Alliance Care Technologies,“Our partnerships with both Eyetelligence and Eyerising in the Gulf Region will provide stand-alone and hospital-based clinics with Glaucoma detection support, Referable Diabetic Retinopathy screening support with grading, and screening support for neovascular age-related macular degeneration (nAMD). We are delighted Prof. Ming is available to share his expertise and advanced technology solutions in person.”
Mounir Sankary, Deputy Consul-General Dubai and Trade Commissioner at Austrade, said,“We at the Australian Trade and Investment Commission (Austrade) are pleased to see the partnership agreement between Eyetelligence and Alliance Care Technologies that will leverage advanced AI capabilities for quality preventative health measures for the people of UAE. These are exactly the sort of partnerships we love to see – a sharing of passion and expertise between Australia and the United Arab Emirates with a spotlight on innovation and reducing the burden of ill health on the community.”
Prof. Ming and members of the Eyetelligence and Alliance Care Technologies' teams demonstrated the groundbreaking technology at the ACT booth throughout the Precision Med Expo conference.
About Alliance Care Technologies:
Alliance Care Technologies develops advanced technology and AI solutions that solve today's most pressing healthcare challenges. The company partners with industry leaders to design individualized solutions that enhance patient experience, streamline administrative processes, manage costs and ultimately improve outcomes. ACT is headquartered in the UAE and Maryland and is a proud member of Hub71 and winner of the Hub71/DOH Outliers Competition in 2021.
About Eyetelligence:
Eyetelligence is an Australian based, international medtech company developing advanced AI software solutions. Our technology analyses full-colour fundus images to screen for eye diseases including: glaucoma, diabetic retinopathy and age related macular degeneration, as well as CVD risk factors prediction.
New York-based healthtech company creation platform Ascertain is investing US$12 (A$18) million in Eyetelligence. Eyetelligence is the first international investment by Ascertain, a first of its kind partnership between Aegis Ventures, a next-generation healthcare-focused venture studio, and Northwell Health, one of the largest health systems in the US. Ascertain is committed to accelerating the development of healthcare AI companies globally with a specific eye on Australia.
About Eyerising International:
Eyerising International is a Melbourne, Australia based global medtech company developing leading-edge eye health technologies. Eyerising is developing affordable, easy to use technology to treat myopia at home, with no drugs or lenses and no side effects through repeated low-level red-light therapy. Backed by growing clinical trial evidence, Eyerising technology has had over 150,000 users of all ages over three years demonstrating real-world benefit.
The Australian Trade and Investment Commission (Austrade) promotes Australian trade, investment, tourism and education to the world. We deliver services to grow Australia's economic prosperity.
We're experts in connecting Australian businesses to the world and our global network turns local market connections and insights into valuable export and investment support.